Antiviral and cellular metabolism interactions between dexelvucitabine and lamivudine

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 6, 2007, Pages 2130-2135

  Hernandez Santiago, Brenda I ^a   Mathew, Judy S ^a   Rapp, Kim L ^a   Grier, Jason P ^a   Schinazi, Raymond F ^a  

^a ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DEXELVUCITABINE; LAMIVUDINE; NUCLEOSIDE TRIPHOSPHATE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL METABOLISM; CONTROLLED STUDY; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOTOPE LABELING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T CELL LYMPHOMA;

ANTI-HIV AGENTS; CELL LINE, TUMOR; CELLS, CULTURED; DRUG INTERACTIONS; DRUG SYNERGISM; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; REVERSE TRANSCRIPTASE INHIBITORS; ZALCITABINE;

EID: 34250197549     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01543-06     Document Type: Article

References (23)

1. Arner, E. S. J., and S. Eriksson. 1993. Deoxycytidine and 2′,3′-dideoxycytidine metabolism in human monocyte-derived macrophages. A study of both anabolic and catabolic pathways. Biochem. Biophys. Res. Commun. 197:1499-1504.
2. Barbara, G., A. Scozzafava, A. Mastrolorenzo, and C. T. Supuran. 2005. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Des. 11:1805-1843.
3. Belen'kii, M. S., and R. F. Schinazi. 1994. Multiple drug effect analysis with confidence interval. Antivir. Res. 25:1-11.
4. Bethell, R., J. Adams, J. De Mys, J. Lippens, A. Richard, C. Ren, P. Collins, C. Struthers-Semple, T. Holdich, and J. Sawyer. 2004. Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754, abstr. 138. 11th Conf. Retrovir. Opportun. Infect., San Francisco, CA, 8 to 11 February 2004.
5. Bethell, R. C., Y. S. Lie, and N. T. Parkin. 2005. In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antivir. Chem. Chemother. 16:295-302.
6. Chou, T.-C. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharm. Rev. 58:621-681.
7. Chou, T.-C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
8. Cohen, C., C. Katlama, R. Murphy, J. Gathe, C. Brinson, G. Richmond, P.-M. Girad, J. Fessel, A. Liappis, E. Puglia, B. Rodwick, J. Nadler, W. O'Brien, K. Arasteh, M. J. Otto, S. Erickson-Viitanen, and R. Levy. 2005. Antiretroviral activity and tolerability of reverset (D-d4FC), a new fluorocytidine nucleoside analog, when used in combination therapy in treatment-experienced patients: results of phase IIb study RVT-203, abstr. WeOaLB103. Third IAS Conf. HIV Pathog. Treatm., Rio de Janeiro, Brazil, 24 to 27 July 2005.
9. Erickson-Viitanen, S., J. T. Wu, G. Shi, S. Unger, R. W. King, B. Fish, R. Klabe, R. Gelenziunas, K. Gallagher, M. J. Otto, and R. F. Schinazi. 2003. Cellular pharmacology of D-d4FC, a nucleoside analog active against drug-resistant HIV. Antivir. Chem. Chemother. 14:39-47.
10. Ericksson, B. F., and R. F. Schinazi. 1989. Combinations of 3′-azido-3′-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 33:663-669.
11. Franklin, D., A. S. Roemer, and L. Placidi. 2004. The global antiviral therapeutics market, p. 159-184. In R. F. Schinazi and D. C. Liotta (ed.), Frontiers in nucleosides and nucleic acids. IHL Press, Tucker, GA.
12. Gu, Z., B. Allard, J. M. de Muys, J. Lippens, R. F. Rando, N. Nguyen-Ba, C. Ren, P. McKenna, D. L. Taylor, and R. C. Bethell. 2006. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50:625-631.
13. Hao, Z., E. E. Stowe, G. Ahluwalia, D. C. Baker, A. K. Hebbler, C. Chisena, S. M. Musser, J. A. Kelley, C.-F. Perno, D. G. Johns, and D. A. Cooney. 1993. Characterization of 2′,3′-dideoxycytidine diphosphocholine and 2′,3′-dideoxycytidine diphosphoethanolamine. Drug Metab. Dispos. 21:738-744.
14. Havlir, D. V., C. Tierney, G. H. Friedland, R. B. Pollard, L. Smeaton, J.-P. Sommadossi, L. Fox, H. Kesseler, K. H. Fife, and D. D. Richman. 2000. In vivo antagonism with zidovudine plus stavudine combination therapy. J. Infect. Dis. 182:321-325.
15. Hernandez-Santiago, B., K. L. Rapp, J. S. Mathew, and R. F. Schinazi. 2004. Lack of antagonistic interactions for the two cytidine analogs Reverset and lamivudine in vitro, abstr. 50:48. HIV DART 2004: Front. Drug Dev. Antiretrovir. Ther., Montego Bay, Jamaica, 12 to 16 December 2004.
16. Krishnan, P., Q. Fu, W. Lam, J.-Y. Liou, G. E. Dutschman, and Y.-C. Cheng. 2002. Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J. Biol. Chem. 277:5453-5459.
17. Martin, L. T., A. Faraj, R. F. Schinazi, G. Gosselin, C. Mathé, J.-L. Imbach, and J.-P. Sommadossi. 1997. Effect of stereoisomerism on the cellular pharmacology of β-enantiomers of cytidine analogs in Hep-G2 cells. Biochem. Pharmacol. 53:75-87.
18. Schinazi, R. F. 1991. Combined therapeutic modalities for viral infections-rationale and clinical potential, p. 110-181. In T. C. Chou and D. C. Rideout (ed.), Synergism and antagonism in chemotherapy. Academic Press, Orlando, FL.
19. Schinazi, R. F., J. Mellors, H. Bazmi, S. Diamond, S. Garber, K. Gallagher, R. Gelenziunas, R. Klabe, M. Pierce, M. Rayner, J.-T. Wu, H. Zhang, J. Hammond, L. Bacheler, D. J. Manion, M. J. Otto, L. J. Stuyver, G. Trainor, D. C. Liotta, and S. Erickson-Viitanen. 2002. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. Antimicrob. Agents Chemother. 46:1394-1401.
20. Shewach, D. S., D. C. Liotta, and R. F. Schinazi. 1993. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′-deoxycytidine kinase. Biochem. Pharmacol. 45:1540-1543.
21. Stuyver, L. J., S. Lostia, M. Adams, J. S. Mathew, B. S. Pai, J. Grier, P. M. Tharnish, Y. Choi, Y. Chong, H. Choo, C. K. Chu, M. J. Otto, and R. F. Schinazi. 2002. Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy-2′,3′-didehydrocytidine analogues. Antimicrob. Agents Chemother. 46:3854-3860.
22. Stuyver, L. J., T. R. McBrayer, D. Schurmann, I. Kravec, A. Beard, L. Cartee, R. F. Schinazi, A. de la Rosa, R. L. Murphy, and M. J. Otto. 2004. Potent antiviral effect of Reverset in HIV-1-infected adults following a single oral dose. Antivir. Ther. 9:529-536.
23. Zhu, Y.-L., G. E. Dutschman, S.-H. Liu, E. G. Bridges, and Y.-C. Cheng. 1998. Anti-hepatitis B virus activity and metabolism of 2′,3′-dideoxy-2′,3′-didehydro-β-L(-) -5-fluorocytidine. Antimicrob. Agents Chemother. 42:1805-1810.